The Biomic group has long experience on method development and validation for the determination of a wide range of pharmaceuticals and on the subsequent application in the analysis of several thousands of clinical samples. A list of developed protocols can be seen here.
Cocaine and metabolites
Cannabis (THC, CBN, CBD)
Acetyl salicylic acid
Diethylamino Hydroxybenzoyl Hexyl Benzonate
In the field of Pharmaceutical BioAnalysis and DMPK, BIOMIC_AUTH offers various possibilities for collaboration. Method development & validation can be performed for any xenobiotic for the analytical application in research or clinical studies. Substances of interest may include pharmaceuticals, natiral products, pesticides, or other drugs and metabolites.
The group works with scientists with specialization in Pharmacokinetics (PK) and have experience in the pharma industry.
Further to this Biomic is closely linked to the Centre for Special Unit for Biomedical Research and Education of the Medical School of AUTh. Biomic with its infrastructure and expertise supports the Clinical Trials Unit for the realization of phase I clinical trials, studies of bioequivalence and/or therapeutic equivalence. Drug monitoring deals with the measurement of pharmaceuticals and their metabolites in biological fluids, mainly blood. Its main focus is on drugs with a narrow therapeutic window. We aim at improving patient care by adjusting the dose of drugs or the drug regimen to assist clinicians in decision making to achieve improved clinical outcome.